Moreover, MITA could sensitize LSCs to chemotherapy (such as Arc-C) and decreased the self-renewal ability of LSCs, suggesting that MITA may have potential applications in the treatment of leukemia (Additional file 5: Figure S4). Here, STING1 is linked to leukemia.